Oxeco PLC Share Price London S.E.
Equities
OXE
GB00B1J5QT30
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- GBX | - |
03-19 | Tissue Regenix annual loss narrows sharply as revenue jumps | AN |
03-19 | Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M | MT |
Sales 2024 * | 27.11M 34.43M 2.71B | Sales 2025 * | 31.03M 39.41M 3.1B | Capitalization | 43.3M 55M 4.33B |
---|---|---|---|---|---|
Net income 2024 * | - 0 0 | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 1.69 x |
Net Debt 2024 * | 2.62M 3.33M 262M | Net Debt 2025 * | 3.84M 4.88M 384M | EV / Sales 2025 * | 1.52 x |
P/E ratio 2024 * |
-366
x | P/E ratio 2025 * |
147
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.32% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Lee
CEO | Chief Executive Officer | 63 | 31/12/18 |
Kirsten Lund
DFI | Director of Finance/CFO | - | 31/12/09 |
David Cocke
DFI | Director of Finance/CFO | 58 | 20/01/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Trevor Phillips
BRD | Director/Board Member | 63 | 04/01/21 |
George Phillips
BRD | Director/Board Member | 64 | 04/01/21 |
Daniel Lee
CEO | Chief Executive Officer | 63 | 31/12/18 |
1st Jan change | Capi. | |
---|---|---|
+9.22% | 33.98B | |
+21.99% | 8.16B | |
+31.37% | 4.26B | |
-30.15% | 2.65B | |
-19.11% | 1.4B | |
-28.03% | 1.27B | |
-33.21% | 1.16B | |
+13.85% | 1.02B | |
-34.50% | 917M |
- Stock Market
- Equities
- TRX Stock
- OXE Stock